Racha Lydia Bouchouka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Racha Lydia Bouchouka has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Laurent Riou
Université de Grenoble Alpes Grenoble France
2 shared publications - Marlène Debiossat
Université de Grenoble Alpes Grenoble France
2 shared publications - Zahia Kabouche
Laboratoire D'obtention de Substances Thérapeutiques (LOST) Université Constantine 1‐Frères Mentouri Constantine Algeria
2 shared publications Ahmed Kabouche
Laboratoire D'obtention de Substances Thérapeutiques (LOST) Université Constantine 1‐Frères Mentouri Constantine Algeria
1 shared publication- Catherine Ghezzi
INSERM, LRB, Université de Grenoble Alpes, 38000 Grenoble, France
1 shared publication - Catherine Ghezzi
Université Grenoble Alpes 1 Grenoble
1 shared publication
Latest Publications
- Open Access
- 22 September 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (9)
Phytochemical Analysis Using LC–MS/MS and Anticancer Activity of Asphodelus tenuifolius Roots: Cell Cycle Arrest, Apoptosis, and In Silico Insights
Asphodelus tenuifolius Cav. (Asphodelaceae) is traditionally used in North African ethnomedicine for inflammatory and oxidative stress‐related disorders. In this study, the hydroethanolic root extract was investigated by LC–HRMS/MS, leading to the identification of 58 metabolites, mainly flavonoids, anthraquinones, and cinnamic acid derivatives. Major constituents included luteolin, emodin, luteolin‐7‐ O ‐β‐D‐glucoside, subaphyllin ( N ‐ trans ‐feruloylputrescine), and N‐trans ‐feruloyltyramine. The extract showed moderate antiproliferative activity against MDA‐MB‐231 and PC‐3 cells, while flow cytometry revealed pronounced apoptosis induction (up to 85%) and significant G0/G1 cell‐cycle arrest. Molecular docking and target prediction suggested multitarget modulation of ERα, AR, AKT1, CDK2, and BCL‐2, particularly by aglycone metabolites. ADMET analysis indicated favorable drug‐likeness and safety profiles. These findings provide the first mechanistic evidence supporting the multitarget anticancer potential of A. tenuifolius roots and highlight their value as a source of bioactive anticancer scaffolds.
- 22 September 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (9)
Open AccessPhytochemical Analysis Using LC–MS/MS and Anticancer Activity of Asphodelus tenuifolius Roots: Cell Cycle Arrest, Apoptosis, and In Silico Insights
Asphodelus tenuifolius Cav. (Asphodelaceae) is traditionally used in North African ethnomedicine for inflammatory and oxidative stress‐related disorders. In this study, the hydroethanolic root extract was investigated by LC–HRMS/MS, leading to the identification of 58 metabolites, mainly flavonoids, anthraquinones, and cinnamic acid derivatives. Major constituents included luteolin, emodin, luteolin‐7‐ O ‐β‐D‐glucoside, subaphyllin ( N ‐ trans ‐feruloylputrescine), and N‐trans ‐feruloyltyramine. The extract showed moderate antiproliferative activity against MDA‐MB‐231 and PC‐3 cells, while flow cytometry revealed pronounced apoptosis induction (up to 85%) and significant G0/G1 cell‐cycle arrest. Molecular docking and target prediction suggested multitarget modulation of ERα, AR, AKT1, CDK2, and BCL‐2, particularly by aglycone metabolites. ADMET analysis indicated favorable drug‐likeness and safety profiles. These findings provide the first mechanistic evidence supporting the multitarget anticancer potential of A. tenuifolius roots and highlight their value as a source of bioactive anticancer scaffolds.
- Open Access
LC-HRMS/MS-Guided Profiling and Biological Evaluation of Stachys duriaei Extracts: Anticancer and Vasorelaxant Mechanisms via Apoptosis and Endothelium-Dependent Pathways
Stachys duriaei (Lamiaceae) remains unexplored despite its pharmacological potential. In this study, for the first time, the antiproliferative, pro-apoptotic, cell cycle arrest, and vasorelaxant effects of the n-butanolic extract (BESD) and a VLC fraction (BF1SD) of Stachys duriaei were investigated. Antiproliferative activity was evaluated on PC3 and MDA-MB-231 cell lines via MTT assay (72 h). Apoptosis (Annexin V-FITC/PI) and cell cycle arrest (PI/RNase) were assessed by flow cytometry (24 h, 250–1000 µg/mL). Vasorelaxant effects were studied ex vivo on rat aortic rings. LC-HRMS/MS was used for phytochemical analysis. BESD showed higher antiproliferative activity (IC50: 196 ± 6 µg/mL for PC3, 182 ± 8 µg/mL for MDA-MB-231) than BF1SD (IC50: 281 ± 6 µg/mL and 273 ± 3 µg/mL, respectively). Apoptosis was dose-dependent, with BF1SD displaying a stronger effect at 1000 µg/mL (67.3 ± 0.5% vs. 49.9 ± 0.7% for BESD). BESD induced G2/M arrest, while BF1SD caused G0/G1 and G2/M arrest. Vasorelaxation was endothelium-dependent, likely mediated by NO. Identified compounds (hyperoside, luteolin-7-glucoside, and rutin) may contribute to these effects. BESD and BF1SD exhibit anticancer and vasorelaxant properties, indicating potential therapeutic use against cancer and cardiovascular diseases. Further studies are needed to isolate active compounds and confirm their effects in vivo.
Open AccessLC-HRMS/MS-Guided Profiling and Biological Evaluation of Stachys duriaei Extracts: Anticancer and Vasorelaxant Mechanisms via Apoptosis and Endothelium-Dependent Pathways
Stachys duriaei (Lamiaceae) remains unexplored despite its pharmacological potential. In this study, for the first time, the antiproliferative, pro-apoptotic, cell cycle arrest, and vasorelaxant effects of the n-butanolic extract (BESD) and a VLC fraction (BF1SD) of Stachys duriaei were investigated. Antiproliferative activity was evaluated on PC3 and MDA-MB-231 cell lines via MTT assay (72 h). Apoptosis (Annexin V-FITC/PI) and cell cycle arrest (PI/RNase) were assessed by flow cytometry (24 h, 250–1000 µg/mL). Vasorelaxant effects were studied ex vivo on rat aortic rings. LC-HRMS/MS was used for phytochemical analysis. BESD showed higher antiproliferative activity (IC50: 196 ± 6 µg/mL for PC3, 182 ± 8 µg/mL for MDA-MB-231) than BF1SD (IC50: 281 ± 6 µg/mL and 273 ± 3 µg/mL, respectively). Apoptosis was dose-dependent, with BF1SD displaying a stronger effect at 1000 µg/mL (67.3 ± 0.5% vs. 49.9 ± 0.7% for BESD). BESD induced G2/M arrest, while BF1SD caused G0/G1 and G2/M arrest. Vasorelaxation was endothelium-dependent, likely mediated by NO. Identified compounds (hyperoside, luteolin-7-glucoside, and rutin) may contribute to these effects. BESD and BF1SD exhibit anticancer and vasorelaxant properties, indicating potential therapeutic use against cancer and cardiovascular diseases. Further studies are needed to isolate active compounds and confirm their effects in vivo.